Table 3.
Initial Equivalence of Study Arms on Individual Differences in Stress and Outcome Variables
| Total (N = 227)
|
Assessment (n = 113)
|
Intervention (n = 114)
|
||||
|---|---|---|---|---|---|---|
| Variable | Mean | SD | Mean | SD | Mean | SD |
| Individual difference: stress | ||||||
| Impact of Events Scale | 26.27 | 14.41 | 26.28 | 14.46 | 26.25 | 14.42 |
| Emotional distress | ||||||
| Profile of Mood States* | 36.32 | 34.26 | 31.38 | 32.11 | 41.42 | 35.67 |
| Anxiety* | 13.10 | 7.39 | 12.02 | 6.91 | 14.17 | 7.72 |
| Depression | 11.76 | 10.37 | 10.83 | 9.32 | 12.68 | 11.28 |
| Anger | 7.85 | 6.44 | 7.49 | 6.70 | 8.22 | 6.19 |
| Confusion | 8.97 | 5.49 | 8.19 | 5.37 | 9.75 | 5.53 |
| Fatigue | 9.58 | 6.29 | 8.65 | 5.97 | 10.49 | 6.49 |
| Vigor | 14.94 | 6.36 | 16.00 | 6.43 | 13.89 | 6.13 |
| Social adjustment | ||||||
| Social Network Index | 6.05 | 2.91 | 5.98 | 2.85 | 6.12 | 2.98 |
| Perceived Social Support | ||||||
| Family | 16.39 | 4.29 | 16.54 | 4.25 | 16.24 | 4.34 |
| Friends* | 16.83 | 3.49 | 16.23 | 3.79 | 17.42 | 3.07 |
| Dyadic Satisfaction Scale* | 3.69 | 1.38 | 3.94 | 1.28 | 3.46 | 1.43 |
| Health behaviors | ||||||
| Food Habits Questionnaire | 43.13 | 9.14 | 42.91 | 9.20 | 43.35 | 9.12 |
| Avoiding fat | 7.30 | 2.82 | 7.29 | 2.76 | 7.30 | 2.90 |
| Food substitution | 12.17 | 3.54 | 12.15 | 3.70 | 12.19 | 3.39 |
| Meat modification | 11.60 | 3.33 | 11.30 | 3.37 | 11.89 | 3.27 |
| Food replacement | 5.72 | 2.12 | 5.85 | 2.20 | 5.58 | 2.03 |
| Fruit/vegetable | 6.34 | 2.00 | 6.32 | 1.81 | 6.37 | 2.19 |
| Exercise, 7-day recall | 17.50 | 27.55 | 19.15 | 29.88 | 15.64 | 24.76 |
| Smoking, cigarettes/d/person† | 10.36 | 9.52 | 9.00 | 8.56 | 12.78 | 11.13 |
| Chemotherapy: recommended, mg/m2/wk‡ | ||||||
| Doxorubicin, n = 168 | 37.49 | 8.39 | 36.27 | 7.27 | 38.67 | 9.22 |
| Cyclophosphamide, n = 187 | 516.28 | 427.24 | 483.02 | 357.08 | 552.14 | 491.36 |
| Methotrexate, n = 28 | 40.14 | 25.73 | 39.61 | 29.94 | 40.96 | 18.76 |
| Fluorouracil, n = 41 | 444.64 | 118.31 | 441.35 | 118.38 | 448.45 | 121.36 |
| Paclitaxel, n = 48 | 121.38 | 29.18 | 123.03 | 30.18 | 119.86 | 28.77 |
| Immune measures | ||||||
| T-lymphocyte counts, K/μL | ||||||
| T3 | 1.28 | 0.59 | 1.25 | 0.51 | 1.32 | 0.66 |
| T4 | 0.90 | 0.43 | 0.86 | 0.39 | 0.93 | 0.47 |
| T8 | 0.43 | 0.22 | 0.42 | 0.19 | 0.43 | 0.25 |
| Blastogenenic response, optical density readings | ||||||
| Unstimulated cells, control | 0.21 | 0.14 | 0.23 | 0.15 | 0.18 | 0.13 |
| Con A, μg/mL, with control values substracted | ||||||
| 10.0 | 0.12 | 0.10 | 0.11 | 0.09 | 0.12 | 0.10 |
| 5.0 | 0.19 | 0.13 | 0.18 | 0.12 | 0.20 | 0.14 |
| 2.5 | 0.19 | 0.14 | 0.18 | 0.12 | 0.21 | 0.16 |
| PHA, μg/mL, with control values subtracted | ||||||
| 10.0 | 0.31 | 0.15 | 0.30 | 0.16 | 0.32 | 0.15 |
| 5.0 | 0.30 | 0.15 | 0.28 | 0.15 | 0.31 | 0.15 |
| 2.5 | 0.28 | 0.15 | 0.27 | 0.15 | 0.29 | 0.15 |
| Natural killer cell count, K/μL | 216.7 | 137.2 | 219.9 | 130.7 | 213.5 | 143.8 |
| Lysis at effector to target ratios, % | ||||||
| 100:1 | 56.38 | 19.33 | 57.12 | 19.45 | 55.63 | 19.27 |
| 50:1 | 47.95 | 18.98 | 48.06 | 18.99 | 47.84 | 19.06 |
| 25:1 | 34.76 | 15.39 | 34.57 | 15.31 | 34.95 | 15.55 |
| 12.5:1 | 23.48 | 12.20 | 23.34 | 12.56 | 23.61 | 11.90 |
| 6.25:1 | 14.32 | 8.37 | 14.41 | 8.74 | 14.23 | 8.04 |
| 3.125:1 | 7.29 | 4.85 | 7.23 | 4.82 | 7.35 | 4.89 |
Abbreviations: SD, standard deviation; Con A, concanavalin A; PHA, phytohemagglutinin.
*
Significant group difference, P < .05.
†
Means based on the 25 smokers in the sample.
‡
Means based on the number of patients receiving the treatment.